Education
About Us
Working with TipRanks
Follow Us
Amgen Inc (HK:4332)
:4332
4332 Stock Chart & Stats
HK$0.18
-HK$665.82(-99.97%)
At close: 4:00 PM EST
HK$0.18
-HK$665.82(-99.97%)
Day’s Range― - ―
52-Week RangeHK$0.19 - HK$1,761.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
HK$1.24T
Enterprise ValueHK$199.23B
Total Cash (Recent Filing)HK$8.03B
Total Debt (Recent Filing)HK$56.20B
Price to Earnings (P/E)<0.1
Beta0.37
Next Earnings
Nov 04, 2025EPS Estimate
39.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)46.76
Shares Outstanding538,361,900
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$2,513.23Price Target Upside1396139.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAMGN reported earnings per share significantly above consensus expectations, leading to an increase in full-year 2025 earnings guidance.
Product DemandAmgen's rare disease portfolio and Imdelltra showed strong demand, contributing to the company's positive financial results.
Regulatory ApprovalRepatha's label was approved for use in adults at increased risk for major adverse cardiovascular events, broadening its reach into the primary prevention space.
Bears Say
Market CompetitionLong-term Repatha risks remain, with anticipated Medicare Part D IRA price controls and potential biosimilar competition after loss of exclusivity.
Product PerformanceSales of Enbrel significantly underperformed compared to consensus expectations, negatively impacting the overall sales figures.
Research And DevelopmentThere is concern over increasing R&D expenses related to obesity, which could affect future margins and EPS.
Amgen News
4332 FAQ
What was Amgen Inc’s price range in the past 12 months?
Amgen Inc lowest stock price was HK$0.18 and its highest was HK$1761.00 in the past 12 months.
What is Amgen Inc’s market cap?
Amgen Inc’s market cap is HK$1.24T.
When is Amgen Inc’s upcoming earnings report date?
Amgen Inc’s upcoming earnings report date is Nov 04, 2025 which is in 16 days.
How were Amgen Inc’s earnings last quarter?
Amgen Inc released its earnings results on Aug 05, 2025. The company reported HK$46.759 earnings per share for the quarter, beating the consensus estimate of HK$41.019 by HK$5.74.
Is Amgen Inc overvalued?
According to Wall Street analysts Amgen Inc’s price is currently Undervalued.
Does Amgen Inc pay dividends?
Amgen Inc does not currently pay dividends.
What is Amgen Inc’s EPS estimate?
Amgen Inc’s EPS estimate is 39.14.
How many shares outstanding does Amgen Inc have?
Amgen Inc has 538,361,900 shares outstanding.
What happened to Amgen Inc’s price movement after its last earnings report?
Amgen Inc reported an EPS of HK$46.759 in its last earnings report, beating expectations of HK$41.019. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Amgen Inc?
Currently, no hedge funds are holding shares in HK:4332
Amgen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$2,513.23 (1396139.68% Upside)
HK$2,513.23 (1396139.68% Upside)
Blogger Sentiment
Bullish
HK:4332 Sentiment 70%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.89%
12-Months-Change
Fundamentals
Return on Equity
99.14%
Trailing 12-Months
Asset Growth
-3.31%
Trailing 12-Months
Company Description
Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
4332 Company Deck
4332 Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Amgen's Q2 2025 earnings call highlighted strong revenue and volume growth, driven by significant increases in sales of key products and a robust rare disease portfolio. The company also demonstrated progress in its R&D pipeline. However, challenges remain with pricing pressures and regulatory changes. Despite these challenges, the positive aspects of the call outweigh the negatives.View all HK:4332 earnings summaries4332 Revenue Breakdown
13.09% Prolia
9.92% Enbrel
6.66% XGEVA
6.65% Repatha
63.69% Other
4332 Stock 12 Month Forecast
Average Price Target
HK$2,513.23
―
Technical Analysis
Options Prices
Currently, No data available
---